Watch List :アクトスの横紋筋融解症 他
2011年 02月 09日
JAMA誌: アクトスを安易に使うな! 2011-02-09
とどめでもないが、さらに、アクトスの横紋融解のwatch list 入り
FDA Adds 13 Drugs to Watch List
http://www.medscape.com/viewarticle/737056
Adverse Event Reporting System (AERS)
Benzonatate (Tessalon, Pfizer) :Death from accidental ingestion in children
Dronedarone hydrochloride (Multaq, Sanofi-Aventis):Drug interaction with warfarin (increased anticoagulant effect)
Epoetin alfa (Epogen/Procrit, Amgen):Possible contamination with shards from glass vial
Gemcitabine hydrochloride (Gemzar, Lilly):Veno-occlusive liver disease
Lanreotide acetate (Somatuline Depot, Beaufour Ipsen) :Pancreatitis, hemorrhagic and necrotizing pancreatitis
Lanthanum carbonate (Fosrenol, Shire):Swallowing complications, gastrointestinal obstruction (attributed to tablet hardness)
Levetiracetam (Keppra, UCB Inc) :Stevens-Johnson's syndrome, toxic epidermal necrolysis
Lithium citrate (Eskalith and Lithobid, Noven):Brugada syndrome
Lopinavir/Ritonavir oral solution (Kaletra, Abbott):Serious adverse events in neonates
Immune globulin G intravenous (human) 5% liquid preparation (Octagam, Octapharma USA):Thromboembolic adverse events
Pioglitazone HCl (Actos, Takeda):Rhabdomyolysis
Ranolazine (Ranexa, Gilead):Drug interaction with statins (rhabdomyolysis)
Sodium oxybate (Xyrem, Jazz):Death
日本では、アクトスの体重増加・浮腫リスクはともかく、骨折リスク、膀胱癌、黄斑変性などの注意喚起不十分だったことからこのことも無視されるかもしれない。
by internalmedicine | 2011-02-09 12:57 | 糖尿病・肥満
